Brandes Investment Partners 13F: Adds $36M to Sanofi (SNY) Stake

Brandes Investment Partners Grows Sanofi Holdings

Brandes Investment Partners expanded its exposure to the healthcare sector by increasing its stake in Sanofi SNY, according to a recent Form 13F filed with the U.S. Securities and Exchange Commission. The filing reflects portfolio holdings as of March 31, 2026, and may not represent the investor's current position today. During the period, the firm lifted its position by 809,844 shares, marking a 27.8% increase from its previous holdings of 2,913,256 shares.

Position Details and Valuation

The added shares brought the total institutional holding to 3,723,100 shares of the drug manufacturer. Based on the valuation details in the regulatory filing, the end-of-period stake carried a total reported value of approximately $164.7 million. The shares were acquired with an estimated cost basis of $46.23 per share during a quarter where institutional buyers adjusted positions across various sectors.

Stock Valuation and Trading Levels

Sanofi shares trade around $44.25, sitting inside a 52-week trading span that stretches from a low of $40.89 to a high of $52.68. The stock trades close to its 50-day moving average of $43.88, while remaining just below its 200-day moving average of $45.39. The company has a trailing P/E ratio of 23.0 and a forward P/E ratio of 7.9, pointing to earnings expectations relative to its share price.

Financial Health and Dividends

The pharmaceutical company generates substantial annual revenue totaling $48.9 billion, supported by a revenue growth rate of 14.6%. Profitability metrics show a net profit margin of 8.1% alongside a return on equity of 5.7%. Income-focused investors track the company's dividend program, which pays an annual rate of $2.42 per share, translating to a dividend yield of 5.7% based on current trading levels.

Inside Sanofi Operations

Sanofi researches, develops, manufactures, and markets therapeutic solutions across the globe. The company focuses on immunology, rare diseases, neurology, oncology, and an extensive portfolio of vaccines, including pediatric formulations and influenza protection. Headquartered in Paris, France, the company partners with various biotech innovators to advance novel treatments and drug delivery platforms.

Looking Ahead at Next Disclosures

Form 13F filings look backward at portfolio holdings from the close of the reporting period and do not necessarily show current trades today. Brandes Investment Partners will need to wait for subsequent quarterly disclosures to see whether the firm builds on this position or trims back. Meanwhile, investors will watch for the company's next financial results scheduled for release on October 30, 2026.